Lyell Immunopharma, Inc. (LYEL)
34.46
+1.05
(+3.14%)
USD |
NASDAQ |
Dec 12, 16:00
34.67
+0.21
(+0.61%)
After-Hours: 20:00
Lyell Immunopharma Shareholders Equity (Quarterly): 329.12M for Sept. 30, 2025
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Ionis Pharmaceuticals, Inc. | 617.97M |
| AnaptysBio, Inc. | -29.42M |
| Ovid Therapeutics, Inc. | 44.70M |
| Cogent Biosciences, Inc. | 302.46M |
| NovaBay Pharmaceuticals, Inc. | 1.634M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 407.96M |
| Total Liabilities (Quarterly) | 78.84M |
| Debt to Equity Ratio | 0.1613 |
| Current Ratio | 10.30 |
| Net Debt Paydown Yield | 0.59% |